Oslo, Norway, April 27. 2020: CardiNor AS today announced that it has secured NOK12 million to commercialise the development of an ELISA test for secretoneurin (SN), a potentially new innovative biomarker for cardiovascular disease. The Norwegian diagnostics company will use the funds for CE marking, initiate US regulatory activities and expanding the range of indications. In addition to existing investors, CardiNor also attracted healthtech specialist Intuitive Investments Group plc.
SN is the only cardiovascular biomarker shown to be associated with biological processes linked to cardiomyocyte Ca2+ handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in major patient cohorts, including ventricular arrhythmia, acute heart failure and acute respiratory failure patients with CVD and severe sepsis.

CardiNor has already been able to demonstrate SN’s potential clinical value in two specific areas – support patient selection for implantable cardioverter defibrillators and heart failure patient discharge eligibility. With access to several world-renowned clinical cohorts, further documentation of SN’s clinical value is under way.

“We are delighted to have closed this latest round and attracted international investors of the calibre of IIG,” commented Dag Christiansen, CEO, CardiNor. “The rise of heart failure worldwide is alarming and described as reaching pandemic levels. Our aim is to develop a routine test for this important marker which we believe will provide clinicians with a key tool for both more accurate risk prediction and patient management.”

“Secretoneurin has the potential to be a game changer in cardiovascular disease,” adds Robert Naylor, CEO of IIG. “We were impressed with the CardiNor team’s expertise and vision and look forward to supporting them as they bring the product though to market.”

 

CardiNor already offers SN as a Research Use Only (RUO) assay. More information can be found at: https://cardinor.com/.